Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Circ Res. 2019 Feb 15;124(4):539–552. doi: 10.1161/CIRCRESAHA.118.314050

Figure 6: PLS regression model predicts QTc shortening by mexiletine for genetic variants.

Figure 6:

A. Locations of 5 LQT3 variants that are included in the clinical trial and were not used for training the model.

B. Comparison of the measured patients’ QTc after mexiletine therapy and the predicted QTc after mexiletine using the PLS regression model.